Sarepta surges on broad approval for muscular dystrophy drug
(Bloomberg) -- Sarepta Therapeutics Inc.’s gene therapy received expanded US approval to include more children with a deadly muscle disease, expanding the market for a controversial treatment that still hasn’t proved its benefit in clinical trials. Most …